Ken Griffin Gamida Cell Ltd. Put Options Transaction History

Citadel Advisors LLC

6 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q1 2024 May 15, 2024	BUY	$0.04 - $0.46 $376 - $4,324	9,400 Added 46.53%	29,600 $1,000
Q4 2023 Feb 14, 2024	BUY	$0.25 - $1.02 $2,575 - $10,506	10,300 Added 104.04%	20,200 $8,000
Q3 2023 Nov 14, 2023	SELL	$0.85 - $1.87 $4,080 - $8,976	-4,800 Reduced 32.65%	9,900 $10,000
Q2 2023 Aug 14, 2023	BUY	$0.73 - $2.37 $8,760 - $28,440	12,000 Added 444.44%	14,700 $28,000
Q1 2023 May 15, 2023	SELL	$0.68 - $1.71 $1,292 - $3,249	-1,900 Reduced 41.3%	2,700 $2,000
Q4 2022 Feb 14, 2023	BUY	$1.15 - $2.1 $5,290 - $9,660	4,600 New	4,600 $5,000

2.2K

Ticker GMDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,319,600
Market Cap $2.29M
Description
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.